{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:33:46Z","timestamp":1790836426847,"version":"4.1.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is a global public health issue, of which the prevalence is about 25% worldwide. The incidence of NAFLD is increasing in patients with obesity, type 2 diabetes (T2DM) and the metabolic syndrome. The crosstalk between gut microbiota and metabolism-related diseases has been raised great concern. Patients with NAPLD were observed with disruption of gut microbiota. Several researches showed that gut microbiota was the determination in the progression of NAFLD by the experiments using fecal microbiota transplants. The application of probiotics, as one of the most important strategies for the regulation of gut microbiota disorder, have been explored whether it is beneficial to gut-related diseases of intestine-distal organs. Some probiotics were showed to improve the liver parameters and phenotype in patients with NAFLD. The oral intake of them might become the effective management for the prevention and treatment of NAFLD. In this review, we summarized the human clinical trials focusing on the effects of probiotics on NAFLD to give some evidential reference for the administration of NAFLD.<\/jats:p>","DOI":"10.3389\/fnut.2023.1155306","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T20:44:07Z","timestamp":1688157847000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials"],"prefix":"10.3389","volume":"10","author":[{"given":"Chujin","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Lonardo","year":"2016","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.clinthera.2021.01.007","article-title":"Nonalcoholic fatty liver disease: a global perspective","volume":"43","author":"Wong","year":"2021","journal-title":"Clin Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.plefa.2010.02.012","article-title":"Fatty liver: role of inflammation and fatty acid nutrition","volume":"82","author":"Byrne","year":"2010","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms17050774","article-title":"The natural course of non-alcoholic fatty liver disease","volume":"17","author":"Calzadilla Bertot","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-Gomez","year":"2017","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40200-015-0170-1","article-title":"Diagnostic accuracy of acylghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients","volume":"14","author":"Mykhalchyshyn","year":"2015","journal-title":"J Diabetes Metab Disord"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/jcm10020346","article-title":"Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a cross-sectional retrospective study","volume":"10","author":"Tarantino","year":"2021","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD)- pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12876-019-1055-4","article-title":"Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial","volume":"19","author":"Saadati","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","article-title":"Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation","volume":"19","author":"Farzanegi","year":"2019","journal-title":"Eur J Sport Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/biom10121702","article-title":"Oxidative stress in NAFLD: role of nutrients and food contaminants","volume":"10","author":"Rives","year":"2020","journal-title":"Biomol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"6889533","DOI":"10.1155\/2021\/6889533","article-title":"The role and mechanism of oxidative stress and nuclear receptors in the development of NAFLD","volume":"2021","author":"Hong","year":"2021","journal-title":"Oxidative Med Cell Longev"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c170012","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr Physiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.23094","article-title":"Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis","volume":"50","author":"Fujita","year":"2009","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of mitochondria in nonalcoholic fatty liver disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/liv.15024","article-title":"Diet and exercise in NAFLD\/NASH: beyond the obvious","volume":"41","author":"Semmler","year":"2021","journal-title":"Liver Int"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"13424","DOI":"10.3390\/ijms222413424","article-title":"It is high time physicians thought of natural products for alleviating NAFLD. Is there sufficient evidence to use them?","volume":"22","author":"Tarantino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetiromon noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/nu11081712","article-title":"Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD)","volume":"11","author":"Ji","year":"2019","journal-title":"Nutrients"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1001\/jama.2012.3507","article-title":"Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis","volume":"307","author":"Newberry","year":"2012","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.phrs.2017.08.001","article-title":"Probiotics and antibiotic-associated diarrhea in children: a review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment","volume":"128","author":"Mantegazza","year":"2018","journal-title":"Pharmacol Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e25657","DOI":"10.1097\/MD.0000000000025657","article-title":"Effect of probiotics on the nutritional status of severe stroke patients with nasal feeding that receive enteral nutrition: a protocol for systematic review and meta-analysis of randomized controlled trials","volume":"100","author":"Liu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.jrn.2020.04.008","article-title":"Effects of probiotics on malnutrition and health-related quality of life in patients undergoing peritoneal dialysis: a randomized controlled trial","volume":"31","author":"Pan","year":"2021","journal-title":"J Ren Nutr"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2019.11.003","article-title":"The microbiome and inflammatory bowel disease","volume":"145","author":"Glassner","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2174\/1389450121666200504075519","article-title":"Nutritional support and probiotics as a potential treatment of IBD","volume":"21","author":"Tarasiuk","year":"2020","journal-title":"Curr Drug Targets"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clnesp.2022.08.002","article-title":"Tailoring gut microbiota with a combination of vitamin K and probiotics as a possible adjuvant in the treatment of rheumatic arthritis: a systematic review","volume":"51","author":"Pereira","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/nu14020354","article-title":"Efficacy of probiotics in rheumatoid arthritis and spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Sanchez","year":"2022","journal-title":"Nutrients"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"9229","DOI":"10.1007\/s00253-019-10156-y","article-title":"Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus","volume":"103","author":"Salga\u00e7o","year":"2019","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1017\/S095442241700018X","article-title":"Probiotics, prebiotics, synbiotics and insulin sensitivity","volume":"31","author":"Kim","year":"2018","journal-title":"Nutr Res Rev"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.cmet.2021.06.014","article-title":"The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease","volume":"33","author":"Zhu","year":"2021","journal-title":"Cell Metab"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1161\/CIRCRESAHA.122.320184","article-title":"Faecalibacterium prausnitzii attenuates CKD via butyrate-renal GPR43 axis","volume":"131","author":"Li","year":"2022","journal-title":"Circ Res"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.3390\/ijms23063167","article-title":"Usefulness of probiotics in the management of NAFLD: evidence and involved mechanisms of action from preclinical and human models","volume":"23","author":"Arellano-Garc\u00eda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.3390\/ijms23158805","article-title":"The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review","volume":"23","author":"Carpi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.4014\/jmb.1906.06064","article-title":"Role of probiotics in human gut microbiome-associated diseases","volume":"29","author":"Kim","year":"2019","journal-title":"J Microbiol Biotechnol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2174\/1389201023666220818145350","article-title":"Prebiotics and probiotics: effects on dyslipidemia and NAFLD\/NASH and the associated mechanisms of action","volume":"24","author":"Rodr\u00edguez-Past\u00e9n","year":"2022","journal-title":"Curr Pharm Biotechnol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1080\/0886022X.2022.2079522","article-title":"Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: a systematic review and meta-analysis","volume":"44","author":"Dai","year":"2022","journal-title":"Ren Fail"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12934-020-1289-4","article-title":"Surface components and metabolites of probiotics for regulation of intestinal epithelial barrier","volume":"19","author":"Liu","year":"2020","journal-title":"Microb Cell Factories"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00394-018-1790-2","article-title":"Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics","volume":"58","author":"Torres","year":"2019","journal-title":"Eur J Nutr"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.18632\/aging.102810","article-title":"Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer\u2019s disease or mild cognitive impairment-a meta-analysis of randomized controlled trials","volume":"12","author":"Den","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell Mol Life Sc"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"32002","DOI":"10.1038\/srep32002","article-title":"Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/hep.28572","article-title":"Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach","volume":"65","author":"Del Chierico","year":"2017","journal-title":"Hepatology"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of fecal microbial communities in patients with liver cirrhosis","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cgh.2013.02.015","article-title":"Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease","volume":"11","author":"Raman","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"Rau","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/gutjnl-2019-318427","article-title":"Leaky gut mechanisms, measurement and clinical implications in humans","volume":"68","author":"Camilleri","year":"2019","journal-title":"Gut"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/imm.13028","article-title":"Interleukin-17\/interleukin-17 receptor axis elicits intestinal neutrophil migration, restrains gut dysbiosis and lipopolysaccharide translocation in high-fat diet-induced metabolic syndrome model","volume":"156","author":"P\u00e9rez","year":"2019","journal-title":"Immunology"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1053\/j.gastro.2017.02.016","article-title":"Gut-specific delivery of T-helper 17 cells reduces obesity and insulin resistance in mice","volume":"152","author":"Hong","year":"2017","journal-title":"Gastroenterology"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/hep.22711","article-title":"VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice","volume":"49","author":"Velayudham","year":"2009","journal-title":"Hepatology"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"659","DOI":"10.5603\/EP.a2017.0055","article-title":"Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition","volume":"68","author":"Kobyliak","year":"2017","journal-title":"Endokrynol Pol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"e21464","DOI":"10.1097\/MD.0000000000021464","article-title":"Protective effect of probiotics in patients with non-alcoholic fatty liver disease","volume":"99","author":"Cai","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J Food Sci"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3760\/cma.j.issn.0578-1426.2018.02.004","article-title":"Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease","volume":"57","author":"Wang","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Ann Hepatol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J Dig Dis"},{"key":"ref83","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","article-title":"A randomised placebo controlled trial of VSL#3\u00ae probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J Am Coll Nutr"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci Rep"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.aohep.2022.100769","article-title":"Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: a double-blind placebo-controlled randomized study","volume":"28","author":"Barcelos","year":"2023","journal-title":"Ann Hepatol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP\u00ae BCMC\u00ae strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Nor","year":"2021","journal-title":"Nutrients"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1155306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T20:44:13Z","timestamp":1688157853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1155306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":89,"alternative-id":["10.3389\/fnut.2023.1155306"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2023.1155306","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"article-number":"1155306"}}